Advertisement

International Journal of Clinical Oncology

, Volume 20, Issue 2, pp 345–350 | Cite as

Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy

  • Eriko Takatori
  • Tadahiro ShojiEmail author
  • Hideo Omi
  • Masahiro Kagabu
  • Fumiharu Miura
  • Satoshi Takeuchi
  • Seisuke Kumagai
  • Akira Yoshizaki
  • Akira Sato
  • Toru Sugiyama
Original Article

Abstract

Background

Neoadjuvant chemotherapy (NAC) is not yet widely recommended for the treatment of stage I/II cervical cancer. However, it may be possible to achieve a favorable outcome by selecting appropriate patients. In the present study, prognostic factors were retrospectively investigated to obtain data for devising individualized NAC.

Patients and methods

The subjects were 33 patients with bulky stage Ib2–IIb squamous cell carcinoma (SCC) of the uterine cervix who gave consent and were scheduled to undergo radical hysterectomy. The patients intravenously received irinotecan 70 mg/m2 on days 1 and 8 and cisplatin 70 mg/m2 on day 1 of a 21-day course, and two courses were performed in principle. The potential prognostic factors investigated were age, performance status (PS), clinical stage, lymph node metastasis and tumor size before NAC, SCC antigen value, anti-tumor response, histological effect of NAC, lymph node metastasis in resected specimens, and postoperative adjuvant therapy after NAC. The impacts of these factors on overall survival (OS) were calculated with the Cox regression model.

Results

According to the univariate analysis, lymph node metastasis before NAC, SCC antigen value after NAC, anti-tumor response, and histological effect of NAC significantly influenced OS. These factors were tested in a multivariate model, and significant prognostic factors were lymph node metastasis before NAC (hazard ratio 0.116, P = 0.027) and anti-tumor response (hazard ratio 0.025, P = 0.003).

Conclusion

The presence or absence of lymph node metastasis by computed tomography imaging was the only significant prognostic factor identified during the pre-NAC period.

Keywords

Prognostic analysis Cervical cancer Bulky tumor Squamous cell carcinoma Neoadjuvant chemotherapy 

Notes

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Morris M, Eifel PJ, Lu J et al (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143CrossRefPubMedGoogle Scholar
  2. 2.
    Rose PG, Bundy BN, Watkins EB et al (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153CrossRefPubMedGoogle Scholar
  3. 3.
    Whitney CW, Sause W, Bundy BN et al (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–1348PubMedGoogle Scholar
  4. 4.
    Pearcey R, Brundage M, Drouin P et al (2002) Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 20:966–972CrossRefPubMedGoogle Scholar
  5. 5.
    Eifel PJ, Winter K, Morris M et al (2004) Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22:872–880CrossRefPubMedGoogle Scholar
  6. 6.
    Green JA, Kirwan JM, Tierney JF et al (2001) Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 358:781–786CrossRefPubMedGoogle Scholar
  7. 7.
    Lukka H, Hirte H, Fyles A et al (2002) Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer–a meta analysis. J Clin Oncol 14:203–212CrossRefGoogle Scholar
  8. 8.
    NCCN (2006) Clinical Practice Guidelines in Oncology-Cervical Cancer-V2. National Comprehensive Cancer NetworkGoogle Scholar
  9. 9.
    Sugiyama T, Nishida T, Kumagai S et al (1999) Combination chemotherapy with irinotecan and cisplatin as neoadjuvant in locally advanced cervical cancer. Br J Cancer 81:95–98CrossRefPubMedCentralPubMedGoogle Scholar
  10. 10.
    Sugiyama T, Nishida T, Kataoka A et al (1996) Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer. Acta Obstet Gynecol Jpn 48:827–834Google Scholar
  11. 11.
    Takeuchi S, Dobashi K, Fujimoto S et al (1991) A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Jpn J Cancer Chemother 18:1681–1689Google Scholar
  12. 12.
    Sugiyama T, Yakushiji M, Noda K et al (2000) Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology 58:31–37CrossRefPubMedGoogle Scholar
  13. 13.
    Shoji T, Takatori E, Hatayama S et al (2010) Phase II study of tri-weekly cisplatin and irinotecan as neoadjuvant chemotherapy for locally advanced cervical cancer. Oncol Lett 1:515–519PubMedCentralPubMedGoogle Scholar
  14. 14.
    Shoji T, Takatori E, Murai M et al (2010) Results of neoadjuvant chemotherapy using tri-weekly CDDP/CPT-11 for locally advanced cervical cancer. Gan To Kagaku Ryoho 37:643–648PubMedGoogle Scholar
  15. 15.
    Shoji T, Takatori E, Omi H, et al. (2012) Neoadjuvant chemotherapy using platinum-based regimens for stage Ib2–II squamous cell carcinoma and non-squamous cell carcinoma of the cervix. In: Li X (ed) Squamous cell carcinoma. Croatia, pp 79–92Google Scholar
  16. 16.
    Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRefGoogle Scholar
  17. 17.
    Tattersall MH, Lorvidhaya V, Vootiprux V et al (1995) Randomized trial of epirubicin and cisplatin chemotherapy followed by pelvic radiation in locally advanced cervical cancer. Cervical Cancer Study Group of the Asian Oceanian Clinical Oncology Association. J Clin Oncol 13:444–451PubMedGoogle Scholar
  18. 18.
    Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer Meta-analysis Collaboration (2003) Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 39:2470–2486CrossRefGoogle Scholar
  19. 19.
    Katsumata N, Yoshikawa H, Kobayashi H et al (2013) Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer 108:1957–1963CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Yamaguchi S, Nishimura R, Yaegashi N et al (2012) Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065). Oncol Rep 28:487–493PubMedGoogle Scholar
  21. 21.
    Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A et al (2002) Concomitant chemoradiation versus neoadjuvant chemotherapy in locally advanced cervical carcinoma: results from two consecutive phase II studies. Ann Oncol 13:1212–1219CrossRefPubMedGoogle Scholar
  22. 22.
    Ryu HS, Kang SB, Kim KT et al (2007) Efficacy of different types of treatment in FIGO stage IB2 cervical cancer in Korea: results of a multicenter retrospective Korean study (KGOG-1005). Int J Gynecol Cancer 17:132–136CrossRefPubMedGoogle Scholar
  23. 23.
    Li R, Lu ST, Si JG et al (2013) Prognostic value of responsiveness of neoadjuvant chemotherapy before surgery for patients with stage IB(2)/IIA(2) cervical cancer. Gynecol Oncol 128:524–529CrossRefPubMedGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2014

Authors and Affiliations

  • Eriko Takatori
    • 1
  • Tadahiro Shoji
    • 1
    Email author
  • Hideo Omi
    • 1
  • Masahiro Kagabu
    • 1
  • Fumiharu Miura
    • 1
  • Satoshi Takeuchi
    • 1
  • Seisuke Kumagai
    • 2
  • Akira Yoshizaki
    • 3
  • Akira Sato
    • 4
  • Toru Sugiyama
    • 1
  1. 1.Department of Obstetrics and GynecologyIwate Medical University School of MedicineMoriokaJapan
  2. 2.Department of Obstetrics and GynecologyNational Hospital Organization Kokura Medical CenterKokuraJapan
  3. 3.Department of GynecologyMiyama HospitalOshuJapan
  4. 4.Department of GynecologyMedical Coat Hachinohe West HospitalHachinoheJapan

Personalised recommendations